Yes, many pediatric practices still administer these vaccines as separate injections rather than using combination products.
While combination vaccines like DTaP-IPV-Hib-HepB (Vaxelis) and DTaP-IPV/Hib (Pentacel) are available and recommended to reduce injection burden, real-world data demonstrates significant variability in practice patterns across the United States.
Current Practice Patterns
Recent U.S. claims data reveals that separate vaccine administration remains common 1:
- Among infants receiving DTaP-IPV/Hib pentavalent vaccine, 95.3% still required separate Hib vaccine doses to complete their series
- For the hepatitis B component specifically, only 59.2% received the second HepB dose on the same day as the first DTaP-IPV/Hib dose
- Only 44.6% received the third HepB dose concurrently with the third DTaP-IPV/Hib dose
- Many infants did not complete their HepB series until 9 months of age due to non-concurrent administration
Factors Driving Separate Administration
Several practical considerations explain why practices continue using separate injections:
Vaccine availability and timing constraints:
- The hexavalent DTaP-IPV-Hib-HepB vaccine cannot be used for the birth dose of hepatitis B (required within 24 hours) 2
- It's not indicated for booster doses at 12-18 months or 4-6 years 2
- The minimum age for the third dose is 24 weeks due to hepatitis B timing requirements 2
Regional and practice-level variations:
- Geographic region, provider type, and health plan type significantly influence whether vaccines are co-administered 1
- Vaccine supply chain and formulary restrictions may limit access to specific combination products
Special population considerations:
- American Indian/Alaska Native infants may preferentially receive PRP-OMP Hib vaccines (2-dose series) for earlier protection, which are incompatible with the hexavalent product requiring a 3-dose series 2
Clinical Implications
The CDC guidelines explicitly state that combination vaccines "can reduce the number of injections administered and improve vaccination coverage" 2. However, practices must balance the benefits of fewer injections against practical constraints including:
- Vaccine inventory management
- Cost considerations for non-program vaccines
- Scheduling flexibility for catch-up immunizations
- Compatibility with previously administered products
When different manufacturers' products are used interchangeably, the same manufacturer's product should ideally complete the series, though vaccination should never be delayed if the original product is unavailable 2.
The persistence of separate vaccine administration reflects real-world operational challenges rather than clinical preference, as combination vaccines demonstrate equivalent immunogenicity and safety profiles 3, 4, 5.